Drug Testing and Analysis · 2019 · 16 citations · 58 references
PharmacyPharmacologyToxicologyDrug MetabolismForensic Pharmaceutical AnalysisForensic ToxicologyCannabinoid PharmacologyCannabinoid ToxicologyCannabis ToxicologyHepatic Drug MetabolismBioanalytical MethodologyCannabinoid Analytical ToxicologyCytochrome P450 Human Liver MicrosomesHigh-resolution Mass AnalysisIllicit Synthetic CannabinoidsSynthetic Cannabinoid IntoxicationSynthetic Cannabinoid ToxicitySynthetic Cannabinoid Toxicology
Abstract Synthetic cannabinoids have proliferated over the last decade and have become a major public health and analytical challenge, critically impacting the clinical and forensic communities. Indazole carboxamide class synthetic cannabinoids have been particularly rampant, and exhibit severe toxic effects upon consumption due to their high binding affinity and potency at the cannabinoid receptors (CB 1 and CB 2 ). MDMB‐CHMINACA, methyl 2‐[1‐(cyclohexylmethyl)‐1 H ‐indazole‐3‐carboxamido]‐3,3‐dimethylbutanoate, a compound of this chemical class, has been identified in forensic casework and is structurally related to several other synthetic cannabinoids. This study presents the first extensive report on the Phase I metabolic profile of MDMB‐CHMINACA, a potent synthetic cannabinoid. The in vitro metabolism of MDMB‐CHMINACA was determined via incubation with human liver microsomes and high‐resolution mass spectrometry. The accurate masses of precursor and fragments, mass error (ppm), and chemical formula were obtained for each metabolite. Twenty‐seven metabolites were identified, encompassing twelve metabolite types. The major biotransformations observed were hydroxylation and ester hydrolysis. Hydroxylations were located predominantly on the cyclohexylmethyl (CHM) moiety. Ester hydrolysis was followed by additional biotransformations, including dehydrogenation; mono‐ and dihydroxylation and ketone formation, each with dehydrogenation. Minor metabolites were identified and reported. The authors propose that CHM‐monohydroxylated metabolites specific to MDMB‐CHMINACA are the most suitable candidates for implementation into bioanalytical assays to demonstrate consumption of this synthetic cannabinoid. Due to the structural similarity of MDMB‐CHMINACA and currently trending synthetic cannabinoids whose metabolic profiles have not been reported, the results of this study can be used as a guide to predict their metabolic pathways.
58
Crystal Structure of the Human Cannabinoid Receptor CB1
Tian Hua, Kiran Vemuri, Mengchen Pu et al. · Cell · 2016 · 678 citations · Full text
High-resolution crystal structure of the human CB1 cannabinoid receptor
Zhenhua Shao, Jie Yin, Karen Chapman et al. · Nature · 2016 · 422 citations · Full text
Crystal Structure of the Human Cannabinoid Receptor CB2
Xiaoting Li, Tian Hua, Kiran Vemuri et al. · Cell · 2019 · 405 citations · Full text